样式: 排序: IF: - GO 导出 标记为已读
-
Risk of incident cancer in patients with Inflammatory Bowel Disease with prior breast cancer: a multicenter cohort study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-11-05 Guillaume Le Cosquer Md, Julien Kirchgesner Md Phd, Cyrielle Gilletta De Saint Joseph Md, Philippe Seksik Md Phd, Aurélien Amiot Md Phd, david laharie md phd, maria nachury md, cléa rouillon md, vered abitbol md phd, alexandre nuzzo md phd, stéphane nancey md phd, mathurin fumery md phd, amélie biron md, nicolas richard md, romain altwegg md, driffa moussata md phd, benedicte caron md phd, mathias
Breast cancer is the most common malignancy observed in patients with inflammatory bowel diseases (IBD). The aim of our study was to evaluate incident cancer rate (recurrence or new-onset cancer) in a cohort of IBD patients with a history of breast cancer according to the subsequent IBD treatment provided.
-
Dysphagia Megalatriensis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-24 Zehra Naseem, Arjun Chatterjee, Yi Qin
-
Patients with Inflammatory Bowel Disease are at Increased Risk for Complications of Herpes Zoster Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-24 Freddy Caldera, Siddharth Singh, Emily E. Zona, Oscar Ramirez Ramirez, Jonathan Inselman, Herbert Heien, Andrew P. Keaveny, Mary S. Hayney, Francis A. Farraye
Patients with inflammatory bowel disease (IBD) are at an increased risk for vaccine-preventable diseases, such as herpes zoster (HZ). The aim of this study was to determine whether complications of HZ are more frequent in patients with IBD than in non-IBD controls.
-
Oxalate Esophagitis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-24 Rita Slim, Hussein Nassereddine
-
Calibration, Clinical Utility, and Specificity of Clinical Decision Support Tools in Inflammatory Bowel Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-24 Dahham Alsoud, João Sabino, Marc Ferrante, Bram Verstockt, Séverine Vermeire
Clinical decision support tools (CDSTs) have been developed to predict response to vedolizumab (VDZ) and ustekinumab (UST) in Crohn’s disease (CD) and ulcerative colitis (UC). In addition to assessing their discrimination performance, our study aimed to evaluate their calibration, clinical utility, and specificity.
-
Hepatitis D Virus Infection Markedly Increases the Risk of Hepatocellular Carcinoma in Patients with Viral B Cirrhosis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-24 Dominique Roulot, Richard Layese, Ségolène Brichler, Nathalie Ganne, Tarik Asselah, Fabien Zoulim, Emmanuel Gordien, Pierre Nahon, Françoise Roudot-Thoraval, DeltaVir and CirVir study groups, Pierre Nahon, Nathalie Ganne, Zahia BenAbdesselam, Tarik Asselah, Fabien Zoulim, Dominique Guyader, Dominique Roulot, Stanislas Pol, Hélène Fontaine, Jean-Didier Grangé, Victor De Lédinghen, Bruno Roche, Thomas
The specific causative role of hepatitis delta virus (HDV) infection in the development of hepatocellular carcinoma (HCC) remains debated and was not specifically demonstrated in patients with cirrhosis. Here we compared HCC incidence in hepatitis B virus (HBV)-HDV coinfected and HBV monoinfected patients with cirrhosis.
-
Hepatitis Delta Virus Testing and Prevalence Among Chronic Hepatitis B Patients Across Three U.S. Safety-net Health Systems Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-24 Robert J. Wong, Mamta K. Jain, Bolin Niu, Yi Zhang, George Therapondos, Mae Thamer
Despite a high prevalence of risk factors associated with hepatitis delta virus (HDV) infection among safety-net populations, data evaluating HDV testing and prevalence are limited. We aim to evaluate HDV testing practices and HDV prevalence among an ethnically diverse, multi-center cohort of safety-net patients with chronic hepatitis B (CHB).
-
Trauma-Informed Care in Gastroenterology: A Survey of Provider Attitudes, Knowledge, and Skills Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-24 Christina Tsai, Sara Abdelhalim, Serre-Yu Wong, Xianhong Xie PhD, Manasi Agrawal, Laurie A. Keefer
-
Outpatient Intensive Nutrition Therapy Improves Survival and Frailty in Males With Alcohol-related ACLF - Randomized Controlled Trial Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-24 Patal Giri, Sunil Taneja, Nancy Sahni, Harish Bhujade, B.K. Padhi, Tanka Karki, Pratibha Garg, Sahaj Rathi, Arka De, Nipun Verma, Madhumita Premkumar, Ajay Duseja
Improvement in the nutritional status of patients with acute-on-chronic liver failure (ACLF) may lead to reduction in morbidity and mortality. This study assessed the impact of dietician-supported outpatient intensive nutrition therapy (OINT) on survival and frailty in patients with alcohol-related ACLF
-
Long-term Effectiveness and Safety of Risankizumab in Patients with Crohn’s Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-24 Adar Zinger, David Choi, Natalie Choi, Evan Fear, Zachary Fine, Russell D. Cohen, David T. Rubin
Risankizumab is a selective interleukin-23 inhibitor approved for the treatment of Crohn’s disease (CD). We report a large long-term real-world experience with risankizumab in CD.
-
Authors’ Reply to the Letter to the Editor Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-24 Sung Won Chung, Won-Mook Choi
-
Acute-onset Type 1 Diabetes Mellitus and Pancreatic Atrophy Caused by an Immune Checkpoint Inhibitor Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-24 Yasuhiro Watanabe, Satoru Iwamoto, Shin’ichi Miyamoto
-
Reply Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-24 Amrit K. Kamboj, Dhyanesh A. Patel, Rena Yadlapati
-
Letter Response to: Hernandez-Rocha C et al, Clin Gastroenterol Hepatol 2024 Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-24 Emily K. Wright, Michael A. Kamm
-
Natural History of Clinically Suspected Isolated Perianal Fistulizing Crohn’s Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-24 Lodoe Sangmo, Baseer Quraishi, Palak Rajauria, Elisabeth Giselbrecht, Jean-Frederic Colombel, Ryan Ungaro, Serre-Yu Wong
-
Outcomes of Long-term Tumor Necrosis Factor Alpha Inhibitor Therapy Beyond 10 Years in Inflammatory Bowel Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-24 Quinten Dicken, Mmeyeneabasi Omede, Ashwin N. Ananthakrishnan
-
Ascites Caused by Peritoneal Leishmaniasis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-23 Suchanart Jitrukthai, Phunchai Charatcharoenwitthaya
-
Kidney Failure, Inflammatory Bowel Disease, and Colectomy Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-23 Chen-Pi Li, Shuo-Yan Gau, Hui-Chin Chang
-
Factors to Consider in the Selection of Noninvasive Fibrosis Tests for Metabolic Dysfunction–Associated Steatotic Liver Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-23 Lucy Gracen, Gunter Hartel, Katharine M. Irvine, Melanie Aikebuse, Patricia C. Valery, Elizabeth E. Powell
-
The Water Lily Sign Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-22 Rachael Hagen, Akaash Mittal, Neil Parikh
-
Interleukin-1 Inhibition in Alcohol-associated Hepatitis: Are We Hitting the Right Target? Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-22 Alberto Calleri, Vijay H. Shah
-
Role of Vibration-controlled Transient Elastography in Liver Transplant Recipients Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-22 Alok Baral, Mohammad Shadab Siddiqui
-
Lowering Rebleeding Risk in Cardiofundal Gastric Varices: The Case for Combined Variceal Embolization and Endovascular Therapies? Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-22 Jiayi Ma, Marwan Ghabril
-
Incidence of Possible Drug-induced Liver Injury Due to Commonly Implicated Agents in the United States Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-22 Craig Lammert, Evgenia Teal, Marwan Ghabril, Naga Chalasani
-
Fecal Microbiota Transplantation (FMT) in Ulcerative Colitis: Holding Out for a Superdonor? Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-22 Jennifer D. Claytor, Jeremiah J. Faith
-
AGA Clinical Practice Update on Esophageal Dysfunction Due to Disordered Immunity and Infection: Expert Review Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-22 Chanakyaram A. Reddy, Emily McGowan, Rena Yadlapati, Kathryn Peterson
This expert review was commissioned and approved by the American Gastroenterological Association (AGA) Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the CPUC and external peer review through standard procedures of Clinical Gastroenterology
-
Fecal Microbiota Transplantation Outcome and Gut Microbiota Composition in Ulcerative Colitis: A Systematic Review and Meta-Analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-21 Mèlanie Valentina Bénard, Marcus C. de Goffau, Justine Blonk, Floor Hugenholtz, Joep van Buuren, Sudarshan Paramsothy, Nadeem Omar Kaakoush, Geert R.A.M. D’Haens, Thomas J. Borody, Michael A. Kamm, Cyriel Y. Ponsioen
Fecal microbiota transplantation (FMT) can induce remission in patients with ulcerative colitis, yet its efficacy needs improvement. We conducted a comprehensive evaluation of the current literature on microbial factors affecting outcome, as well as a meta-analysis on some of the largest datasets regarding composition.
-
Online-Only vs Conventional Publication of Original Research Articles: A Randomized Controlled Trial Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-19 Fasiha Kanwal, Gina Reitenauer, Thoba Khumalo Petrovic, Nicholas J. Tomeo, Yan Liu, Aaron P. Thrift
-
High Hospitalization Rates and Risk Factors Among Frail Patients With Cirrhosis: A 10-year Population-based Cohort Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-18 Bima J. Hasjim, Mohsen Mohammadi, Salva N. Balbale, Mitchell Paukner, Therese Banea, Haoyan Shi, Al’ona Furmanchuk, Lisa B. VanWagner, Lihui Zhao, Andres Duarte-Rojo, Julianna Doll, Sanjay Mehrotra, Daniela P. Ladner, CAPriCORN Team
Cirrhosis-related inpatient hospitalizations have increased dramatically over the past decade. We used a longitudinal dataset capturing a large metropolitan area in the United States from 2011 to 2021 to evaluate contemporary hospitalization rates and risk factors among frail patients with cirrhosis.
-
Gut Goo: Physiology, Diet, and Therapy of Intestinal Mucus and Biofilms in Gastrointestinal Health and Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-18 John Damianos, Nada Abdelnaem, Michael Camilleri
The gastrointestinal tract has remarkable capacity to withstand considerable insults from exposure to abrasive food particles, chemicals, allergens, and pathogenic microbes. Maintaining a robust epithelial barrier sequesters these potentially harmful substances in the lumen, preventing absorption into the systemic circulation. Normal functioning of this barrier is central in diverse physiological processes
-
No Impact of Concomitant Medications on Efficacy and Safety of Biologics and Small Molecules for Ulcerative Colitis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-11 Dhruv Ahuja, Guangyong Zou, Virginia Solitano, Gaurav Syal, Han Hee Lee, Christopher Ma, Vipul Jairath, Siddharth Singh
Although participants with inflammatory bowel diseases in clinical trials of biologics and small molecule drugs (henceforth, advanced therapies) frequently receive several medications concomitantly, it is unclear how they modify treatment effect.
-
Low Prevalence of Submucosal Cancer in Large Right Colon Large Superficial Lesions: Matter of Case Selection! Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-09 Jeremie Jacques, Mathieu Pioche, Yutaka Saito
-
The Critical Role of Accurate Diagnosis and Risk-stratification in Safe and Precise Endoscopic Ultrasound-guided Pancreatic Cyst Ablation Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-09 Matthew Yoder, Somashekar G. Krishna
-
Neoplastic Progression Risk in Females With Barrett’s Esophagus: A Systematic Review and Meta-Analysis of Individual Patient Data Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-05 Pauline A. Zellenrath, Laurelle van Tilburg, Roos E. Pouw, Rena Yadlapati, Yonne Peters, Michael B. Ujiki, Prashanthi N. Thota, Norihisa Ishimura, Stephen J. Meltzer, Noam Peleg, Won-Tak Choi, John V. Reynolds, Alexandros D. Polydorides, Arjun D. Koch, Judith Honing, Manon C.W. Spaander
Females with Barrett’s esophagus (BE) have a lower risk of neoplastic progression than males, but sufficiently powered risk analyses are lacking. This systematic review and meta-analysis of individual patient data (IPD) aimed to provide more robust evidence on neoplastic progression risk in females.
-
Editorial: Getting to the Real Skinny on GLP-1RAs and the Risk of Aspiration During Endoscopy Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-02 Jennifer Christie
-
Global Progression Rates of Precursor Lesions for Gastric Cancer: A Systematic Review and Meta-Analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-10-01 Anne I. Hahn, Duco T. Mülder, Robert J. Huang, Margaret J. Zhou, Benjamin Blake, Omonefe Omofuma, John D. Murphy, Daniela S. Gutiérrez-Torres, Ann G. Zauber, James F. O’Mahony, M. Constanza Camargo, Uri Ladabaum, Jennifer M. Yeh, Chin Hur, Iris Lansdorp-Vogelaar, Reinier Meester, Monika Laszkowska
Whether gastric cancer (GC) precursor lesions progress to invasive cancer at similar rates globally remains unknown. We conducted a systematic review and meta-analysis to determine the progression of precursor lesions to GC in countries with low versus medium/high incidence.
-
Endoscopic Submucosal Dissection Provides Hemostasis by Curative Resection for a Large Bleeding and Obstructive Duodenal Lipoma Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-09-27 Mark Tawfik, Chloe Lahoud, Sherif Andrawes
-
An Overview of the Challenging Process of Prior Authorization: Medical Necessity for a Better Way Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-09-18 Stephen T. Amann, Eric D. Shah, Louis J. Wilson
-
Small Bowel Bleeding Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-09-12 Daniel Wild, Cynthia Ko
-
Updates in Colon Endoscopic Mucosal Resection Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-09-10 Mohammad Bilal, Heiko Pohl
-
Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-09-05 Mohammad Shehab, Fatema Alrashed, Abdulwahab Alsayegh, Usama Aldallal, Christopher Ma, Neeraj Narula, Vipul Jairath, Siddharth Singh, Talat Bessissow
Treatment options for moderate to severe ulcerative colitis (UC) are increasing rapidly, but the lack of comparative efficacy trials makes treatment choices a clinical challenge. This network-meta-analysis aimed to compare the relative efficacy of biologics and small molecules in achieving remission in patients with moderate to severe UC.
-
The Association Between Obesity and Malignant Progression of Barrett’s Esophagus: A Systematic Review and Dose-Response Meta-Analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-09-03 Mie Thu Ko, Tom Thomas, Emily Holden, Ian L.P. Beales, Leo Alexandre
Obesity is a risk factor for both Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC). However, it is unclear whether obesity drives the malignant progression of BE. We aimed to assess whether obesity is associated with high-grade dysplasia (HGD) or cancer in patients with BE.
-
Epidemiology of Elderly Onset IBD: A Nationwide Population-Based Cohort Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Siddharth Singh, Gry Juul Poulsen, Tania Hviid Bisgaard, Linéa Bonfils, Tine Jess
We examined the incidence and natural history of patients with very elderly onset (herein referred to as very late-onset) inflammatory bowel diseases (IBDs) (≥ 70 years of age at diagnosis), compared with patients diagnosed between 60 and 69 years of age in Denmark.
-
Beta-Blockers Lower First Decompensation in Patients With Cirrhosis and Enduring Portal Hypertension After Etiological Treatment Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Laura Turco, Madalina-Gabriela Taru, Giovanni Vitale, Horia Stefanescu, Federica Mirici Cappa, Sonia Berardi, Anna Baldan, Roberto Di Donato, Paolo Pianta, Vittoria Vero, Luca Vizioli, Lucia Maria Procopciuc, Bogdan Procopet, Maria Cristina Morelli, Fabio Piscaglia
Nonselective beta-blockers (NSBBs) can lower the risk of first decompensation in patients with cirrhosis and clinically significant portal hypertension (CSPH) (identified by a hepatic venous pressure gradient ≥10 mm Hg) with active etiology. Our aim was to examine the effect of NSBBs on first decompensation occurrence in patients with cirrhosis and enduring CSPH after etiological treatment.
-
Global Prevalence of Advanced Liver Fibrosis and Cirrhosis in the General Population: A Systematic Review and Meta-analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Mohammad Zamani, Shaghayegh Alizadeh-Tabari, Veeral Ajmera, Siddharth Singh, Mohammad Hassan Murad, Rohit Loomba
Limited data exist regarding the estimate of the prevalence of advanced liver fibrosis and cirrhosis in the general population. Therefore, we conducted a systematic review and meta-analysis to evaluate the global prevalence and risk factors of advanced fibrosis and cirrhosis.
-
Alcohol Rehabilitation Within 3 Months After Alcohol Hepatitis and Survival - A National Analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Lucia Parlati, Charlotte Mouliade, Eric Nguyen Khac, Mathis Collier, Stylianos Tzedakis, Samir Bouam, Anoisia Courtois, Marion Corouge, Alexandre Louvet, Stanislas Pol, Philippe Sogni, Amine Benyamina, Jürgen Rehm, Philippe Mathurin, Vincent Mallet, Demosthenes research group
There is limited understanding of the benefits of alcohol rehabilitation after alcohol hepatitis (AH).
-
Biopsy Proteome Score Performs Well as an Effect Measure in a Gluten Challenge Trial of Celiac Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Anette Johansen, Geir Kjetil F. Sandve, Joseph R. Maxwell, Glennda Smithson, Ludvig M. Sollid, Jorunn Stamnaes
Development of novel treatments for celiac disease is dependent on precise tools to monitor changes in gluten-induced mucosal damage. Current histology measures are subjective and difficult to standardize. Biopsy proteome scoring is an objective alternative to histology which is based on robust changes in biological pathways that directly reflect gluten-induced mucosal damage. In this study, we aimed
-
High Diagnostic Value of Transient Elastography for Advanced Fibrosis and Cirrhosis in Patients With Chronic Hepatitis Delta Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Dominique Roulot, Ségolène Brichler, Richard Layese, Louis D’alteroche, Nathalie Ganne-Carrie, Christiane Stern, Antonio Saviano, Vincent Leroy, Françoise Roudot-Thoraval, Victor De Ledinghen, DELTAVIR study group, Véronique Loustaud-Ratti, Christine Silvain, Souad Benali, Patrick Ingiliz, Martial Gouton, Dominique Guyader, Bruno Roche, Olivier Chazouillères, Tarik Asselah, Marianne Ziol
Liver biopsy remains the gold standard for fibrosis staging in patients with chronic hepatitis delta (CHD). Here, we comparatively evaluated the performance of transient elastography (TE) and biomarkers for the diagnosis of liver fibrosis in patients with CHD.
-
Accuracy of Computer-aided Diagnosis in Colonoscopy Varies According to Polyp Location: A Systematic Review and Meta-analysis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Tommy Rizkala, Cesare Hassan, Yuichi Mori, Marco Spadaccini, Giulio Antonelli, Evelien Dekker, Britt B.S.L. Houwen, Oliver Pech, Sebastian Baumer, Emanuele Rondonotti, Franco Radaelli, James Weiquan Li, Daniel von Renteln, Masashi Misawa, Antonio Facciorusso, Roberta Maselli, Silvia Carrara, Alessandro Fugazza, Antonio Capogreco, Kareem Khalaf, Harsh Patel, Prateek Sharma, Douglas Rex, Alessandro Repici
Computer-aided diagnosis (CADx) assists endoscopists in differentiating between neoplastic and non-neoplastic polyps during colonoscopy. This study aimed to evaluate the impact of polyp location (proximal vs. distal colon) on the diagnostic performance of CADx for ≤5 mm polyps.
-
Missed Opportunity to Triage Patients With Irritable Bowel Syndrome to Multidisciplinary Therapy Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Bhavana Tetali, William D. Chey, Stacy B. Menees
-
Early Biological Therapy Within 12 Months of Diagnosis Leads to Higher Transmural Healing Rates in Crohn’s Disease Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Joana Revés, Agnes Fernandez-Clotet, Ingrid Ordás, Anthony Buisson, Maëva Bazoge, Constance Hordonneau, Pierre Ellul, Melvin D’Anastasi, Ainara Elorza, Marta Aduna, Iago Rodríguez-Lago, Inês Sousa Lajas, Ana Raimundo, Paulo J.G. Bettencourt, Gonçalo Freire, Pedro Sousa, Ana Primitivo, Ivo Delgado, Jordi Rimola, Joana Torres
Transmural healing (TH) is emerging as a potential Crohn's disease (CD) treatment target. Early biological treatment seems to be associated with improved disease outcomes, but its impact on TH remains unclear. We aimed to assess the impact of early biological treatment initiation on TH and its influence on CD prognosis.
-
Long-Term Continuous Terlipressin Infusion Improves Cardiac Reserve in Patients With Decompensated Cirrhosis Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-30 Ryma Terbah, Anoop N. Koshy, Avik Majumdar, Karl Vaz, Adam Testro, Marie Sinclair
Cardiac dysfunction is a key factor in the pathogenesis of hepatorenal syndrome, for which terlipressin is the recommended first-line treatment. This study investigates whether long-term terlipressin can ameliorate the subclinical cardiac dysfunction observed in decompensated cirrhosis.
-
North American Expert Consensus on the Post-procedural Care of Patients After Per-oral Endoscopic Myotomy Using a Delphi Process Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-28 Dennis Yang, Abdul Mohammed, Rena Yadlapati, Andrew Y. Wang, Thurarshen Jeyalingam, Peter V. Draganov, Ernesto Robalino Gonzaga, Muhammad K. Hasan, Alexander Schlachterman, Ming-Ming Xu, Ahmed Saeed, Aziz Aadam, Reem Z. Sharaiha, Ryan Law, Louis M. Wong Kee Song, Monica Saumoy, John E. Pandolfino, Makoto Nishimura, Michel Kahaleh, Joo Ha Hwang, Robert Bechara, Vani JA. Konda, John M. DeWitt, Prashant
There is significant variability in the immediate post-operative and long-term management of patients undergoing per-oral endoscopic myotomy (POEM), largely stemming from the lack of high-quality evidence. We aimed to establish a consensus on several important questions on the after care of post-POEM patients through a modified Delphi process.
-
Predictors of Functional Cure of Chronic Hepatitis B Virus Infection: A Long-Term Follow-Up Study Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-28 Jia-Feng Wu, Chi-San Tai, Kai-Chi Chang, Yuh-Jue Chen, Chien-Ting Hsu, Huey-Ling Chen, Yen-Hsuan Ni, Mei-Hwei Chang
A functional cure is an essential endpoint in the management of patients with chronic hepatitis B virus (HBV) infection. We evaluated the cumulative probability and predictors of functional cure in patients with chronic HBV infection after hepatitis B e antigen (HBeAg) seroconversion.
-
Thiopurines and the Risk of Cancer in Patients With Inflammatory Bowel Disease and Reference Individuals Without Inflammatory Bowel Disease – A Danish Nationwide Cohort Study (1996-2018) Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-28 Mads Damsgaard Wewer, Gasper Letnar, Klaus Kaae Andersen, Mikkel Malham, Vibeke Wewer, Jakob Benedict Seidelin, Flemming Bendtsen, Johan Burisch
Thiopurine therapy is a cornerstone in the treatment of inflammatory bowel disease (IBD). We aimed to assess the effect of thiopurines on cancer risk in IBD according to drug exposure and age.
-
Reliability of Intestinal Ultrasound for Evaluating Crohn’s Disease Activity Using Point-of-care and Central Reading Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-28 Thomas M. Goodsall, Yoon-Kyo An, Jane M. Andrews, Jakob Begun, Antony B. Friedman, Andrew Lee, Peter J. Lewindon, Paul Spizzo, Nick Rodgers, Kirstin M. Taylor, Lauren S. White, Rune Wilkens, Emily K. Wright, Lily Zou, Bryan R. Maguire, Claire E. Parker, Julie Rémillard, Kerri L. Novak, Remo Panaccione, Brian G. Feagan, Vipul Jairath, Christopher Ma, Robert V. Bryant
Intestinal ultrasound (IUS) is increasingly used to assess Crohn’s disease (CD) activity in clinical practice. However, application in clinical trials has been limited by heterogeneous scoring methods and concerns about reliability. We aimed to determine the inter- and intra-rater reliability of locally and centrally read IUS parameters for evaluating CD using prospectively performed scans.
-
Validation of a National Pathology Database for Colonoscopy Quality Reporting and Assurance Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-28 Andrew J. Gawron, Grace Mckee, Jason A. Dominitz, Yiwen Yao, Mary Whooley, Tonya Kaltenbach
-
Racial, Ethnic, and Geographic Disparities in Digestive Diseases Mortality in the United States, 2000–2019 Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-28 Wafa A. Aldhaleei, Michael B. Wallace, Yan Bi, Ann M. Rusk, Akshaya Srikanth Bhagavathula
The global burden of digestive diseases mortality has been increasing over the last 3 decades. However, little is known about disparities in digestive diseases–specific mortality in the United States. This study aimed to examine racial, ethnic, and state- and county-level disparities in digestive diseases mortality rate in the United States between 2000 and 2019.
-
Reply on “Tenofovir is Associated With a Better Prognosis Than Entecavir for Hepatitis B Virus-related Hepatocellular Carcinoma” Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-27 Kai-Chun Chang, Tung-Hung Su, Jia-Horng Kao
-
Rectal Cavernous Hemangioma Clin. Gastroenterol. Hepatol. (IF 11.6) Pub Date : 2024-08-27 Xi Zhou, Jiaojun Li, Jing Shan